MedTrace Logo

Post-marketing Surveillance (PMS) Use-Result Surveillance With SPIKEVAX BIVALENT, SPIKEVAX X Injection, SPIKEVAX JN Injection and SPIKEVAX IN PRE-FILLED SYRINGE

NCT06333704 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 4207

Last updated 2026-04-16

No results posted yet for this study

Summary

The main objective of the surveillance is to evaluate the incidence of the adverse events (AEs), and other safety-related information in South-Korean population.

Conditions

Interventions

BIOLOGICAL

SPIKEVAX Bivalent BA.1

No study drug will be administered during this study as this is an observational study.

BIOLOGICAL

SPIKEVAX Bivalent BA.4/5

No study drug will be administered during this study as this is an observational study.

BIOLOGICAL

SPIKEVAX XBB.1.5

No study drug will be administered during this study as this is an observational study.

BIOLOGICAL

SPIKEVAX JN.1

No study drug will be administered during this study as this is an observational study.

Sponsors & Collaborators

  • C&R Research, Inc.

    collaborator INDUSTRY

  • ModernaTX, Inc.

    lead INDUSTRY

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-03-10
Primary Completion
2029-03-29
Completion
2029-03-29

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06333704 on ClinicalTrials.gov